Piper Sandler Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $8.00

Health Catalyst (NASDAQ:HCAT) had its price target cut by Piper Sandler from $12.00 to $8.00 in a research note published on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms have also commented on HCAT. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday, January 8th. Stephens boosted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 21st. Wells Fargo & Company reduced their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Finally, Royal Bank of Canada reduced their price target on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.20.

Health Catalyst Price Performance

Health Catalyst stock opened at $5.55 on Tuesday. The stock has a market cap of $337.72 million, a price-to-earnings ratio of -4.11 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 1 year low of $5.32 and a 1 year high of $10.14. The firm has a 50-day moving average of $6.64 and a two-hundred day moving average of $7.37.

Insider Buying and Selling

In other Health Catalyst news, CFO Jason Alger sold 19,599 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the transaction, the chief financial officer now owns 86,712 shares in the company, valued at approximately $721,443.84. This represents a 18.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the transaction, the insider now owns 236,950 shares in the company, valued at $2,118,333. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,169 shares of company stock worth $629,068 in the last 90 days. 2.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HCAT. Quantbot Technologies LP acquired a new position in Health Catalyst during the 4th quarter valued at approximately $29,000. Quest Partners LLC acquired a new position in Health Catalyst during the 3rd quarter valued at approximately $34,000. nVerses Capital LLC acquired a new position in Health Catalyst during the 3rd quarter valued at approximately $59,000. Stoneridge Investment Partners LLC purchased a new stake in shares of Health Catalyst in the 4th quarter valued at $77,000. Finally, Martin Worley Group purchased a new stake in shares of Health Catalyst in the 4th quarter valued at $78,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.